Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Crohn's Disease Therapeutics Market - Outlook and Forecast 2022-2027
The market for therapeutics to treat Crohn’s disease is projected to experience a compound annual growth rate (CAGR) of 10.35% from 2022 to 2027, reaching a value of USD 23.14 billion by 2027, compared to USD 12.82 billion in 2021. Crohn’s disease is an inflammatory bowel disease (IBD) characterized by inflammation of the digestive tract, resulting in symptoms such as abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The market for inflammatory bowel disease treatment can be divided into two types: Crohn’s disease and ulcerative colitis, with Crohn’s disease dominating the global market.
According to estimates from the latest research, the United States had the highest prevalence of Crohn’s disease in 2020, followed by the United Kingdom and China. The increasing prevalence of Crohn’s disease is driving the growth of the market for Crohn’s disease drugs. In 2019, it was estimated that one million people in the US were affected by Crohn’s disease.
|No. of Pages||
USD 12.8 billion in 2020
Drug Class, Gender Type, Age Group, Disease Type, and Geography Type
|No. of Companies Mentioned||
There are currently over 100 assets in various stages of development in the Crohn’s disease portfolio. The majority of industry-sponsored drugs in active clinical development for Crohn’s disease are in Phase II. Anti-interleukin and integrin antibodies are the dominant drugs in the Crohn’s disease drug pipeline.
The clinical trial portfolio includes over 150 trials in various stages of development. The majority of industry-sponsored drugs in active clinical development for Crohn’s disease are in Phase II. The distribution of clinical trials across Phases I-IV indicates that the majority of trials for Crohn’s disease are in the early and mid-stages of development, with 75-80% in Phases I-II and only 16% in Phases III-IV. The US leads in the number of global Crohn’s disease clinical trials.
The adoption of biologics, such as anti-tumor necrosis factor (TNF), anti-interleukin, and integrin antibodies, is widespread for the treatment of inflammatory diseases, including Crohn’s disease. These therapies are considered satisfactory for patients who do not respond adequately to steroids and aminosalicylates. However, some patients may experience a loss of response to these therapies, particularly anti-TNFs. With the last biologic approved for Crohn’s disease being Stelara (ustekinumab) in 2016, there is a demand for therapies with new mechanisms of action that are less immunogenic. Several new classes of therapies are expected to enter the market in the coming years, such as anti-integrin and interleukin inhibitors, which offer better clinical profiles and more convenient dosing for patients.
The increasing prevalence of Crohn’s disease worldwide has contributed to the significant growth of the market. Estimates suggest that the number of Crohn’s disease patients in the eight major markets (8MM) was 1,830,704 in 2020, and this is projected to reach 2,191,344 from 2021 to 2027.
Microbiome-based therapeutics with novel mechanisms are emerging as a treatment option for Crohn’s disease. Major players in the industry are developing innovative products and investing heavily in research and development, as well as engaging in significant acquisitions and collaborations. For example, Takeda has entered into a global licensing, co-development, and co-promotion agreement with Enterome S.A. Other companies, including BiomX, Synlogics, 4D Pharma, and Vedanta Bioscience, are also focusing on microbiome-based therapeutics for the treatment of Crohn’s disease. These players employ both organic and inorganic growth strategies to strengthen their product portfolios.
There have already been multiple successful launches of new therapies for the treatment of moderate-to-severe Crohn’s disease. These include biologics such as Humira (adalimumab), Remicade (infliximab), and Cimzia (certolizumab pegol) targeting anti-TNFs, as well as Entyvio (vedolizumab) and Tysabri (natalizumab), which are anti-integrins. Additionally, Stelara (ustekinumab) and Skyrizi (risankizumab-rzaa), which are interleukin (IL) 12 and 23 inhibitors, have been approved. Currently, five major companies—Johnson & Johnson (J&J), AbbVie, Takeda, UCB, and Biogen—have branded drugs approved for the treatment of Crohn’s disease.
The market is segmented based on various factors, including drug class, gender type, age group, disease type, and geography type.
Segmentation by Drug Class
Segmentation by Gender Type
Segmentation by Age Group
49 yrs. & below
50 yrs. & Above
Segmentation by Disease Type
Small/Large intestinal type
Large intestinal type
Small intestinal type
Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
Drug Class: TNF-Alpha inhibitors are projected to hold a significant share in the global Crohn’s disease therapeutics market, but other drug classes are expected to exhibit the highest growth rate during the forecast period. The recent approval of biologics like Skyrizi (risankizumab-rzaa) is anticipated to drive the global Crohn’s disease treatment market. While the market has relied on anti-tumor necrosis factor (anti-TNF) therapies for many years, there has been a growing focus on researching novel mechanisms of action (MOAs) to address non-response issues. The launch of new drugs, particularly targeting moderate-to-severe patients, between 2023-2025 is expected to contribute significantly to the growth of the Crohn’s disease market. Biologics such as anti-integrin and interleukin inhibitors are gaining traction due to their improved clinical profiles and convenient dosing for patients.
Gender type: Women are expected to hold a substantial share in the global Crohn’s disease therapeutics market, reflecting a slight female predominance over males.
Disease type: The small/large intestinal type is expected to have a significant share in the global Crohn’s disease treatment market, with the small intestinal type projected to be the fastest-growing segment during the forecast period.
Age Group: Individuals aged 49 years and below are projected to account for a large share in the global Crohn’s disease therapeutics market. While Crohn’s disease can occur at any age, it is most commonly diagnosed in adolescents and adults between the ages of 20 and 30.
The United States currently dominates the Crohn’s disease therapeutics market, driven by accessible healthcare, increased awareness, and technological advancements. However, the United Kingdom is expected to experience rapid growth with a high compound annual growth rate (CAGR) in the Crohn’s disease drug market due to improved healthcare access and quality, increased disease management awareness, and rising healthcare expenditure. The emergence of biosimilars in emerging markets like China and Japan has the potential to significantly impact the therapeutic landscape in those regions.
The market for Crohn’s disease treatment is currently dominated by several companies that offer generic medications, as well as selective pharmaceutical and biotechnology companies that provide patented or commercially developed drugs for the treatment of this condition. In 2012, the U.S. Food and Drug Administration (FDA) approved the TNF-Alpha agent Humira (Adalimumab) as a treatment for Crohn’s Disease. Subsequently, in 2016, the FDA approved Stelara (ustekinumab), followed by Skyrizi (risankizumab-rzaa) in 2022, both specifically for treating Crohn’s Disease. While generic products continue to hold a significant share in the industry, the introduction of biologics and other targeted therapies signifies a paradigm shift in this therapeutic domain throughout the projected period.
The prominent players offering drugs in the Crohn’s Disease treatment market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb, Gilead Bioscience, Celltrion, RedHill Biopharma, Landos Biopharma, ReiStone Biopharma, Eli Lilly and Company, and many others.
Key companies profiled in this report include AbbVie Inc (AbbVie), Johnson & Johnson (J&J), Takeda Pharmaceutical Co Ltd (Takeda), Biogen Inc (Biogen), UCB SA (UCB), Boehringer Ingelheim International GmbH (Boehringer), AstraZeneca Plc (AstraZeneca), Bristol-Myers Squibb Co (BMS), RedHill Biopharma Ltd, CellTrion.
Recent Industry Developments
In June 2022, AbbVie made an announcement regarding the approval of SKYRIZI (risankizumab-rzaa) by the U.S. Food and Drug Administration (FDA). This approval marked a significant milestone as SKYRIZI became the first and only specific interleukin-23 (IL-23) inhibitor approved for the treatment of adults with moderately to severely active Crohn’s disease (CD). The approval was granted based on the positive results from two clinical studies, namely ADVANCE and MOTIVATE, which evaluated the efficacy and safety of risankizumab in adults with moderately to severely active Crohn’s disease compared to placebo. The studies assessed two different doses of risankizumab, 600 mg and 1200 mg.
In May 2022, AbbVie shared positive topline results from its Phase 3 maintenance study called U-ENDURE. This study evaluated the use of upadacitinib in adult patients with moderate to severe Crohn’s disease who had an inadequate response or were intolerant to conventional or biologic therapy. The results demonstrated that a higher percentage of patients treated with either dose of upadacitinib (15 mg or 30 mg once daily) achieved the co-primary endpoints of endoscopic response and clinical remission at one year (week 52), compared to those on placebo. The study also showed positive results for the secondary endpoint of endoscopic remission.
In March 2022, Ossium Health, Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for OSSM-001. OSSM-001 is a mesenchymal stem cell (MSC) product intended for the treatment of refractory perianal fistulas in patients with Crohn’s disease. This acceptance by the FDA paves the way for Ossium to initiate patient screening and enrollment in a multi-center Phase 1 clinical trial to evaluate the safety and efficacy of OSSM-001. The trial is expected to commence by the end of 2022.
Key Questions Answered
What is the projected size of the global market for Crohn’s disease therapeutics?
The global market for Crohn’s disease therapeutics is projected to reach USD 23.14 billion by 2027.
What is the expected growth rate of the global market for Crohn’s disease therapeutics?
The global market for Crohn’s disease therapeutics is expected to grow at a compound annual growth rate (CAGR) of 10.35% from 2022 to 2027.
Who are the major players in the market for Crohn’s disease treatment?
AbbVie Inc (AbbVie), Johnson & Johnson (J&J), Takeda Pharmaceutical Co Ltd (Takeda), Biogen Inc (Biogen), and UCB SA (UCB) are the key players in the market for Crohn’s disease treatment.
What are the factors driving the growth of the global market for Crohn’s disease therapeutics?
The adoption of biologics and the increasing prevalence of Crohn’s disease are the key factors driving the growth of the global market for Crohn’s disease therapeutics.
Which country has the largest market share in the global market for Crohn’s disease therapeutics?
The United States holds the largest market share in the global market for Crohn’s disease therapeutics.